Blincyto-话题@MedSci

#Blincyto#

10篇内容 | 570人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2029687, encodeId=6c94202968e4f, content=<a href='/topic/show?id=0743352266' target=_blank style='color:#2F92EE;'>#Blincyto#</a>, objectTitle=又有抗癌新药来了！礼来Verzenio、安进Blincyto被纳入优先审评, objectType=article, longId=184663, objectId=917318466353, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=917318466353, replyNumber=0, likeNumber=34, createdTime=2020-02-19, rootId=0, userName=12498a1cm67暂无昵称, userId=1fa82500120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=917318466353, moduleTitle=又有抗癌新药来了！礼来Verzenio、安进Blincyto被纳入优先审评, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=917318466353)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2029686, encodeId=84bd202968660, content=<a href='/topic/show?id=0743352266' target=_blank style='color:#2F92EE;'>#Blincyto#</a>, objectTitle=安进宣布两项三期双特异性抗体BLINCYTO（靶向CD3和CD19）治疗小儿复发性急性淋巴细胞白血病患者的阳性结果, objectType=article, longId=180054, objectId=6917180054ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6917180054ef, replyNumber=0, likeNumber=38, createdTime=2020-01-22, rootId=0, userName=12498a1cm67暂无昵称, userId=1fa82500120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6917180054ef, moduleTitle=安进宣布两项三期双特异性抗体BLINCYTO（靶向CD3和CD19）治疗小儿复发性急性淋巴细胞白血病患者的阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6917180054ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2029685, encodeId=335320296850f, content=<a href='/topic/show?id=0743352266' target=_blank style='color:#2F92EE;'>#Blincyto#</a>, objectTitle=2019 EHA：Amgen双特异性抗体Blincyto治疗白血病的五年生存数据喜人, objectType=article, longId=168697, objectId=cf5816869ebe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf5816869ebe, replyNumber=0, likeNumber=33, createdTime=2019-10-22, rootId=0, userName=12498a1cm67暂无昵称, userId=1fa82500120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf5816869ebe, moduleTitle=2019 EHA：Amgen双特异性抗体Blincyto治疗白血病的五年生存数据喜人, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cf5816869ebe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2029684, encodeId=d8b42029684f9, content=<a href='/topic/show?id=0743352266' target=_blank style='color:#2F92EE;'>#Blincyto#</a>, objectTitle=Blincyto适应症扩容：MRD阳性ALL, objectType=article, longId=134487, objectId=05e813448ebe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=05e813448ebe, replyNumber=0, likeNumber=38, createdTime=2019-01-25, rootId=0, userName=12498a1cm67暂无昵称, userId=1fa82500120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=05e813448ebe, moduleTitle=Blincyto适应症扩容：MRD阳性ALL, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=05e813448ebe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2029683, encodeId=50472029683c8, content=<a href='/topic/show?id=0743352266' target=_blank style='color:#2F92EE;'>#Blincyto#</a>, objectTitle=喜讯！FDA加速批准安进BiTE免疫疗法Blincyto治疗儿科Ph-急性淋巴细胞白血病（ALL）, objectType=article, longId=76569, objectId=1570e65698b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1570e65698b, replyNumber=0, likeNumber=38, createdTime=2017-02-25, rootId=0, userName=12498a1cm67暂无昵称, userId=1fa82500120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1570e65698b, moduleTitle=喜讯！FDA加速批准安进BiTE免疫疗法Blincyto治疗儿科Ph-急性淋巴细胞白血病（ALL）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1570e65698b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2029682, encodeId=6d7120296822d, content=<a href='/topic/show?id=0743352266' target=_blank style='color:#2F92EE;'>#Blincyto#</a>, objectTitle=FDA授予安进BiTE免疫疗法Blincyto治疗儿科急性淋巴细胞白血病（ALL）的优先审查资格, objectType=article, longId=67544, objectId=c7dd6e544b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c7dd6e544b6, replyNumber=0, likeNumber=26, createdTime=2017-04-07, rootId=0, userName=12498a1cm67暂无昵称, userId=1fa82500120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c7dd6e544b6, moduleTitle=FDA授予安进BiTE免疫疗法Blincyto治疗儿科急性淋巴细胞白血病（ALL）的优先审查资格, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c7dd6e544b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2029681, encodeId=fd9e202968144, content=<a href='/topic/show?id=0743352266' target=_blank style='color:#2F92EE;'>#Blincyto#</a>, objectTitle=BiTE免疫疗法Blincyto治疗费城染色体阴性白血病III期临床成功, objectType=article, longId=63534, objectId=bde06353427, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bde06353427, replyNumber=0, likeNumber=33, createdTime=2016-10-03, rootId=0, userName=12498a1cm67暂无昵称, userId=1fa82500120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bde06353427, moduleTitle=BiTE免疫疗法Blincyto治疗费城染色体阴性白血病III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bde06353427)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2029678, encodeId=046f20296e82d, content=<a href='/topic/show?id=0743352266' target=_blank style='color:#2F92EE;'>#Blincyto#</a>, objectTitle=ASH 2014：安进BiTE免疫疗法Blincyto有效治疗急性淋巴细胞白血病（ALL）, objectType=article, longId=43800, objectId=5ccf43800e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ccf43800e2, replyNumber=0, likeNumber=41, createdTime=2015-07-24, rootId=0, userName=12498a1cm67暂无昵称, userId=1fa82500120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ccf43800e2, moduleTitle=ASH 2014：安进BiTE免疫疗法Blincyto有效治疗急性淋巴细胞白血病（ALL）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ccf43800e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2029680, encodeId=bfd7202968018, content=<a href='/topic/show?id=0743352266' target=_blank style='color:#2F92EE;'>#Blincyto#</a>, objectTitle=FDA批准安进高价罕见白血病新药Blincyto, objectType=article, longId=44501, objectId=ca82445019b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ca82445019b, replyNumber=0, likeNumber=28, createdTime=2015-06-09, rootId=0, userName=12498a1cm67暂无昵称, userId=1fa82500120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ca82445019b, moduleTitle=FDA批准安进高价罕见白血病新药Blincyto, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ca82445019b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2029679, encodeId=5bf220296e906, content=<a href='/topic/show?id=0743352266' target=_blank style='color:#2F92EE;'>#Blincyto#</a>, objectTitle=ASH 2014：Blincyto治疗ALL有效, objectType=article, longId=44369, objectId=e6c744369e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e6c744369e3, replyNumber=0, likeNumber=22, createdTime=2015-05-06, rootId=0, userName=12498a1cm67暂无昵称, userId=1fa82500120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e6c744369e3, moduleTitle=ASH 2014：Blincyto治疗ALL有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e6c744369e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Blincyto

2020-05-29

12498a1cm67暂无昵称 (审核中...)

前往app查看评论内容

#Blincyto#

又有抗癌新药来了！礼来Verzenio、安进Blincyto被纳入优先审评

2020-02-19

12498a1cm67暂无昵称 (审核中...)

前往app查看评论内容

#Blincyto#

安进宣布两项三期双特异性抗体BLINCYTO（靶向CD3和CD19）治疗小儿复发性急性淋巴细胞白血病患者的阳性结果

2020-01-22

12498a1cm67暂无昵称 (审核中...)

前往app查看评论内容

#Blincyto#

2019 EHA：Amgen双特异性抗体Blincyto治疗白血病的五年生存数据喜人

2019-10-22

12498a1cm67暂无昵称 (审核中...)

前往app查看评论内容

#Blincyto#

Blincyto适应症扩容：MRD阳性ALL

2019-01-25

12498a1cm67暂无昵称 (审核中...)

前往app查看评论内容

#Blincyto#

喜讯！FDA加速批准安进BiTE免疫疗法Blincyto治疗儿科Ph-急性淋巴细胞白血病（ALL）

2017-02-25

12498a1cm67暂无昵称 (审核中...)

前往app查看评论内容

#Blincyto#

FDA授予安进BiTE免疫疗法Blincyto治疗儿科急性淋巴细胞白血病（ALL）的优先审查资格

2017-04-07

12498a1cm67暂无昵称 (审核中...)

前往app查看评论内容

#Blincyto#

BiTE免疫疗法Blincyto治疗费城染色体阴性白血病III期临床成功

2016-10-03

12498a1cm67暂无昵称 (审核中...)

前往app查看评论内容

#Blincyto#

ASH 2014：安进BiTE免疫疗法Blincyto有效治疗急性淋巴细胞白血病（ALL）

2015-07-24

12498a1cm67暂无昵称 (审核中...)

前往app查看评论内容

#Blincyto#

FDA批准安进高价罕见白血病新药Blincyto

2015-06-09

12498a1cm67暂无昵称 (审核中...)

前往app查看评论内容

#Blincyto#

ASH 2014：Blincyto治疗ALL有效

2015-05-06

科室
- - 订阅+
  - 更多科室
工具
服务